Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc Com V.ICO


Primary Symbol: ICOTF

iCo Therapeutics Inc is a Canada based biotechnology company. It is involved in the Research and development of ophthalmic indications. The company identifies, develops, and commercialize drug candidates with clinical history, and re-doses, reformulates and develops these drug candidates to treat sight and life-threatening diseases. Its in-licensed assets are iCo-008 and the Oral AmpB Delivery System. iCo-008 is a human monoclonal antibody targeting eotaxin-1 that acts as a messenger between...


GREY:ICOTF - Post by User

Post by ForexWhaleon Nov 06, 2018 9:14am
108 Views
Post# 28929468

Something interesting is happening for sure

Something interesting is happening for sureWhen I checked F2G Pharma adviosry board which is another well established anti-fungal R & D company in UK,  Dr. John Perfect and Prof David Denning both are mentioned as advisors.

https://www.f2g.com/advisors/

Below link is also useful to judge ICO potential.

https://www.f2g.com/antifungal-market/

I think with the phase 1 results much better than anticipated and compared to competition, something is brewing up with regard to these advisory board hirings and a possible JV might be in the pipeline. Its inevitable that they will combine forces with established anti-fungal R & D companies to fast track development of ICO-019.
<< Previous
Bullboard Posts
Next >>